FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009556446> ?p ?o ?g. }

• W3009556446 endingPage "630" @default.
• W3009556446 startingPage "622" @default.
• W3009556446 abstract "BACKGROUND: Heparin-induced thrombocytopenia (HIT) can put cardiac surgery patients at a high risk of lethal complications. If anti-PF4/heparin antibodies (anti-PF4/Hep Abs) are present, 2 strategies exist to prevent intraoperative aggregation during bypass surgery: first, using an alternative anticoagulant, and second, using heparin combined with an antiaggregant. The new P2Y12 inhibitor, cangrelor, could be an attractive candidate for the latter strategy; several authors have reported its successful use. The present in vitro study evaluated cangrelor’s ability to inhibit heparin-induced platelet aggregation in the presence of anti-PF4/Hep Abs. METHODS: Platelet-poor plasma (PPP) from 30 patients with functional anti-PF4/Hep Abs was mixed with platelet-rich plasma (PRP) from 5 healthy donors. Light transmission aggregometry was used to measure platelet aggregation after adding 0.5 IU·mL−1 of heparin (HIT) to the plasma, and this was compared with samples spiked with normal saline (control) and samples spiked with cangrelor 500 ng·mL−1 and heparin 0.5 IU·mL−1 (treatment). Friedman test with post hoc Dunn-Bonferroni test was used for between-group comparisons. RESULTS: Heparin 0.5 IU·mL−1 triggered aggregation in 22 of 44 PPP–PRP mixtures, with a median aggregation of 86% (interquartile range [IQR], 69–91). The median aggregation of these 22 positive samples’ respective control tests was 22% (IQR, 16–30) (P < .001). Median aggregation in the cangrelor-treated samples was 29% (IQR, 19–54) and significantly lower than the HIT samples (P < .001). Cangrelor inhibited heparin-induced aggregation by a median of 91% (IQR, 52–100). Cangrelor only reduced heparin-induced aggregation by >95% in 10 of the 22 positive samples (45%). Cangrelor inhibited heparin-induced aggregation by <50% in 5 of the 22 positive samples (22%) and by <10% in 3 samples (14%). CONCLUSIONS: This in vitro study found that cangrelor was an unreliable inhibitor of heparin-induced aggregation in the presence of anti-PF4/Hep Abs. We conclude that cangrelor should not be used as a standard antiaggregant for cardiac patients affected by HIT during surgery. Unless cangrelor’s efficacy in a particular patient has been confirmed in a presurgery aggregation test, other strategies should be chosen." @default.
• W3009556446 created "2020-03-13" @default.
• W3009556446 creator A5011260014 @default.
• W3009556446 creator A5011580858 @default.
• W3009556446 creator A5043247664 @default.
• W3009556446 creator A5081932296 @default.
• W3009556446 creator A5089053529 @default.
• W3009556446 date "2020-02-24" @default.
• W3009556446 modified "2023-09-27" @default.
• W3009556446 title "Potential and Limitations of the New P2Y12 Inhibitor, Cangrelor, in Preventing Heparin-Induced Platelet Aggregation During Cardiac Surgery: An In Vitro Study" @default.
• W3009556446 cites W1864087818 @default.
• W3009556446 cites W1983577961 @default.
• W3009556446 cites W1989314872 @default.
• W3009556446 cites W1999386605 @default.
• W3009556446 cites W2012145261 @default.
• W3009556446 cites W2026561579 @default.
• W3009556446 cites W2031081426 @default.
• W3009556446 cites W2036176846 @default.
• W3009556446 cites W2049376452 @default.
• W3009556446 cites W2062503515 @default.
• W3009556446 cites W2068295374 @default.
• W3009556446 cites W2082043630 @default.
• W3009556446 cites W2113913660 @default.
• W3009556446 cites W2129290564 @default.
• W3009556446 cites W2141233689 @default.
• W3009556446 cites W2166356559 @default.
• W3009556446 cites W2433067092 @default.
• W3009556446 cites W2605106484 @default.
• W3009556446 cites W2605967338 @default.
• W3009556446 cites W2606196396 @default.
• W3009556446 cites W2607174980 @default.
• W3009556446 cites W2782860679 @default.
• W3009556446 cites W2800849798 @default.
• W3009556446 cites W2802560894 @default.
• W3009556446 cites W2902914300 @default.
• W3009556446 cites W2911683411 @default.
• W3009556446 cites W2955815822 @default.
• W3009556446 cites W68178237 @default.
• W3009556446 cites W8062481 @default.
• W3009556446 doi "https://doi.org/10.1213/ane.0000000000004700" @default.
• W3009556446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32102014" @default.
• W3009556446 hasPublicationYear "2020" @default.
• W3009556446 type Work @default.
• W3009556446 sameAs 3009556446 @default.
• W3009556446 citedByCount "8" @default.
• W3009556446 countsByYear W30095564462020 @default.
• W3009556446 countsByYear W30095564462021 @default.
• W3009556446 countsByYear W30095564462022 @default.
• W3009556446 countsByYear W30095564462023 @default.
• W3009556446 crossrefType "journal-article" @default.
• W3009556446 hasAuthorship W3009556446A5011260014 @default.
• W3009556446 hasAuthorship W3009556446A5011580858 @default.
• W3009556446 hasAuthorship W3009556446A5043247664 @default.
• W3009556446 hasAuthorship W3009556446A5081932296 @default.
• W3009556446 hasAuthorship W3009556446A5089053529 @default.
• W3009556446 hasBestOaLocation W30095564461 @default.
• W3009556446 hasConcept C119060515 @default.
• W3009556446 hasConcept C126322002 @default.
• W3009556446 hasConcept C159973064 @default.
• W3009556446 hasConcept C2776708134 @default.
• W3009556446 hasConcept C2777557582 @default.
• W3009556446 hasConcept C2778205648 @default.
• W3009556446 hasConcept C2778589496 @default.
• W3009556446 hasConcept C2778914503 @default.
• W3009556446 hasConcept C2780076745 @default.
• W3009556446 hasConcept C2993802102 @default.
• W3009556446 hasConcept C3018697912 @default.
• W3009556446 hasConcept C42219234 @default.
• W3009556446 hasConcept C49059817 @default.
• W3009556446 hasConcept C71924100 @default.
• W3009556446 hasConcept C89560881 @default.
• W3009556446 hasConcept C98274493 @default.
• W3009556446 hasConceptScore W3009556446C119060515 @default.
• W3009556446 hasConceptScore W3009556446C126322002 @default.
• W3009556446 hasConceptScore W3009556446C159973064 @default.
• W3009556446 hasConceptScore W3009556446C2776708134 @default.
• W3009556446 hasConceptScore W3009556446C2777557582 @default.
• W3009556446 hasConceptScore W3009556446C2778205648 @default.
• W3009556446 hasConceptScore W3009556446C2778589496 @default.
• W3009556446 hasConceptScore W3009556446C2778914503 @default.
• W3009556446 hasConceptScore W3009556446C2780076745 @default.
• W3009556446 hasConceptScore W3009556446C2993802102 @default.
• W3009556446 hasConceptScore W3009556446C3018697912 @default.
• W3009556446 hasConceptScore W3009556446C42219234 @default.
• W3009556446 hasConceptScore W3009556446C49059817 @default.
• W3009556446 hasConceptScore W3009556446C71924100 @default.
• W3009556446 hasConceptScore W3009556446C89560881 @default.
• W3009556446 hasConceptScore W3009556446C98274493 @default.
• W3009556446 hasIssue "2" @default.
• W3009556446 hasLocation W30095564461 @default.
• W3009556446 hasLocation W30095564462 @default.
• W3009556446 hasOpenAccess W3009556446 @default.
• W3009556446 hasPrimaryLocation W30095564461 @default.
• W3009556446 hasRelatedWork W1474881703 @default.
• W3009556446 hasRelatedWork W156171836 @default.
• W3009556446 hasRelatedWork W1973995242 @default.
• W3009556446 hasRelatedWork W1988399394 @default.
• W3009556446 hasRelatedWork W2030331651 @default.

• next